Gland Pharma’s Q3 FY23 revenue stood at Rs. 938 Cr with gross margin of 54%
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility